BAGSVAERD, DENMARK--(Marketwired - April 22, 2013) - At Novo Nordisk’s Annual General Meeting on 20 March 2013, it was decided to reduce the company’s B share capital from DKK 452,512,800 to DKK 442,512,800 by cancellation of part of the company’s portfolio of own B shares at a nominal value of DKK 10,000,000 divided into 10,000,000 B shares of DKK 1 each.
Articles of Association of Novo Nordisk A/S:
http://hugin.info/2013/R/1694756/557436.pdf
Company announcement No 28 / 2013:
http://hugin.info/2013/R/1694756/557435.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Thomson Reuters ONE
[HUG#1694756]
Further information
Media:
Anne Margrethe Hauge
+45 4442 3450
Email Contact
Ken Inchausti (US)
+1 609 514 8316
Email Contact
Investors:
Kasper Roseeuw Poulsen
+45 4442 4303
Email Contact
Frank Daniel Mersebach
+45 4442 0604
Email Contact
Lars Borup Jacobsen
+45 3075 3479
Email Contact
Jannick Lindegaard (US)
+1 609 786 4575
Email Contact
